Zur Kurzanzeige

dc.contributor.authorChen, Christopher L.H.
dc.contributor.authorYoung, Sherry H.Y.
dc.contributor.authorGan, Herminigildo
dc.contributor.authorSingh, Rajinder
dc.contributor.authorLao, Annabelle Y.
dc.contributor.authorBaroque, Alejandro C.
dc.contributor.authorChang, Hui Meng
dc.contributor.authorHiyadan, John Harold B.
dc.contributor.authorChua, Carlos L.
dc.contributor.authorAdvincula, Joel M.
dc.contributor.authorMuengtaweepongsa, Sombat
dc.contributor.authorChan, Bernard PL
dc.contributor.authorde Silva, H. Asita
dc.contributor.authorde Silva, H. Asita
dc.contributor.authorSuwanwela, Nijasri
dc.contributor.authorPoungvarin, Niphon
dc.contributor.authorChankrachang, Siwaporn
dc.contributor.authorWong, Ka Sing Lawrence
dc.contributor.authorEow, Gaik Bee
dc.contributor.authorNavarro, Jose C.
dc.contributor.authorVenketasubramanian, Narayanaswamy
dc.contributor.authorLee, Chun Fan
dc.contributor.authorBousser, Marie-Germaine
dc.contributor.author
dc.date.accessioned2024-04-23T08:12:54Z
dc.date.available2024-04-23T08:12:54Z
dc.date.issued2013-06-18
dc.identifier.citationChen C, Venketasubramanian N, Lee C, Wong K, Bousser M, Navarro J, Gan H, Lao A, Baroque A, Lokin J, Hiyadan J, Sarfati M, Fangonillo R, Ambasing N, Chua C, San Jose M, Advincula J, Berame E, Canete M, Venketasubramanian N, Young S, Mamauag M, Tay S, Pande S, Thirugnanam U, Singh R, Chang H, De Silva D, Chan B, Sharma V, Luen T, Poungvarin N, Muengtaweepongsa S, Towanabut S, Suwanwela N, Chotickanuchit S, Chankrachang S, Nitinun S, de Silva H, Ranawake U, Wijekoon N, Wong K and Eow G (2013). Chinese medicine Neuroaid efficacy on Stroke recovery. Stroke. 44(8), 2093-2100.en
dc.identifier.issn0039-2499
dc.identifier.urihttps://hdl.handle.net/20.500.14353/358
dc.description.abstractBACKGROUND AND PURPOSE-: Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour time window. METHODS-: This multicenter, double-blind, placebo-controlled trial randomized 1100 patients with a National Institutes of Health Stroke Scale score 6 to 14, within 72 hours of onset, to trial medications for 3 months. The primary outcome was a shift in the modified Rankin Scale. Secondary outcomes were modified Rankin Scale dichotomy, National Institutes of Health Stroke Scale improvement, difference in National Institutes of Health Stroke Scale total and motor scores, Barthel index, and mini-mental state examination. Planned subgroup analyses were performed according to age, sex, time to first dose, baseline National Institutes of Health Stroke Scale, presence of cortical signs, and antiplatelet use. RESULTS-: The modified Rankin Scale shift analysis-adjusted odds ratio was 1.09 (95% confidence interval, 0.86-1.32). Statistical difference was not detected between the treatment groups for any of the secondary outcomes. Subgroup analyses showed no statistical heterogeneity for the primary outcome; however, a trend toward benefit in the subgroup receiving treatment beyond 48 hours from stroke onset was noted. Serious and nonserious adverse events rates were similar between the 2 groups. CONCLUSIONS-: MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. Longer treatment duration and follow-up of participants with treatment initiated after 48 hours may be considered in future studies.en
dc.description.sponsorshipThe CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) study was funded, in part, by the CHIMES Society, a nonprofit organization. Moleac (Singapore) provided grants and other resources to the CHIMES Society, which had sole discre-tion on use. The National Medical Research Council of Singapore provided funding (NMRC/1288/2011 and NMRC/1096/2006) to conduct this study in Singapore and for the overall coordination of the study.en
dc.language.isoenen
dc.publisherAmerican Heart Association, Inc.en
dc.relation.urien
dc.subjectNeuroAiDen
dc.subjectPoststroke recoveryen
dc.subjectMLC601en
dc.subjectNeuroAiDen
dc.subjectStroke unit careen
dc.subjectTraditional Chinese medicineen
dc.subjectCHIMESen
dc.subjectChInese Medicine NeuroAiD Efficacy on Stroke Recoveryen
dc.subject.lcshMedicine, Chineseen
dc.subject.lcshClinical trialsen
dc.subject.lcshCerebrovascular diseaseen
dc.subject.lcshTherapeuticsen
dc.subject.lcshNeuroprotective agentsen
dc.subject.meshStrokeen
dc.subject.meshIschemic Strokeen
dc.subject.meshThrombolytic Therapyen
dc.subject.meshAspirinen
dc.subject.meshStroke Rehabilitationen
dc.titleChinese medicine neuroaid efficacy on stroke recovery: A double-blind, placebo-controlled, randomized studyen
dc.typeArticleen
dcterms.accessRightsOpen accessen
dc.citation.journaltitleStrokeen
dc.citation.volume40en
dc.citation.issue8en
dc.citation.firstpage2093en
dc.citation.lastpage2100en
dc.identifier.essn1524-4628
dc.identifier.doi10.1161/STROKEAHA.113.002055
local.isIndexedByScopusen


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige